As a novelty in the previously mentioned antiangiogenics, the anti-endoglin antibody TRC105 eliminates CD105+ cells in the TME in a neuroblastoma animal model, increasing the effect of immunotherapy with anti-GD2 antibody dinutuximab and activated natural killer cells [146]. This evidence concerns the gene ENG and neuroblastoma.